Cue Biopharma (CUE) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on injectable therapeutics for autoimmune and inflammatory diseases using the Immuno-STAT® platform to selectively modulate disease-specific T cells, aiming to improve efficacy and minimize off-target effects.

• Principal executive offices located in Boston, Massachusetts.

Financial performance and metrics

• As of December 31, 2025, held $27.1 million in cash and cash equivalents.

• Existing cash expected to fund operations into the first quarter of 2027.

• Market value of public float as of March 13, 2026, was approximately $37,998,848, with 97,283,278 shares held by non-affiliates at $0.3906 per share.

• Historical net tangible book value as of December 31, 2025, was $26.3 million, or $0.27 per share.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for general corporate purposes, including R&D, clinical trials, acquisitions or in-licensing, collaborations, personnel, debt repayment, working capital, and capital expenditures.

• Proceeds may be temporarily invested in short-term, investment-grade, interest-bearing instruments or U.S. government securities.

• Management retains broad discretion over allocation of proceeds.